Breaking Finance News

Zacks Investment Research upgraded Nektar Therapeutics (NASDAQ:NKTR) to Hold in a report released today.

Boasting a price of $17.11, Nektar Therapeutics (NASDAQ:NKTR) traded -3.17% lower on the day. With the last stock price close up 8.83% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. NKTR has recorded a 50-day moving average of $18.22 and a 200-day moving average of $15.72. 457,547 shares of the stock were exchanged, down from an average trading volume of 1,178,010

Zacks Investment Research has upgraded Nektar Therapeutics (NASDAQ:NKTR) to Hold in a statement released on 9/29/2016.

See Chart Below

Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics has a 52 week low of $9.92 and a 52 week high of $19.98 The company’s market cap is currently $0.

General Information About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *